Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma
Neuroblastoma
High-risk and relapsed disease: MYCN amplification, ALK mutations and anti-GD2 therapy.
Live from ClinicalTrials.gov, fetched 2026-11-12 11:36 UTC. Every row links to its source record.
Drug trials updated in the last 16 months
160
Phase 1 to 3, interventional
For relapsed or refractory disease
48%
77 trial titles name relapsed, refractory or recurrent disease
Led by industry
14%
22 trials with a company as lead sponsor
11 of the 160 neuroblastoma trials are Phase 3; 12 were stopped early
Drug trials in this cancer with a registry update in the last 16 months, by phase. Each bar is split by where the trial stands today.
Running or not yet startedCompletedStopped early (terminated, withdrawn or suspended)
A trial that spans two phases counts as the later one. Stopped early is the registry status, whatever the reason given. Source: ClinicalTrials.gov, fetched live.
Programs: each drug in each segment
A program is one drug in one segment of neuroblastoma (biomarker, line of therapy, setting), so the same drug can be Phase 3 in one segment and Phase 1 in another. Segments are read from each trial's title and conditions by published rules; 45 of 160 trials name no segment and are listed as Untagged.
Segment:All1L1L · MaintenanceAdjuvantAdvanced or metastaticALKALK · Relapsed or refractoryGD2GD2 · Relapsed or refractoryLocally advancedMaintenanceRelapsed or refractoryUntagged
Modality:AllAntibodyAntibody-drug conjugateBispecific antibodyCell therapyOther or not recognisedRadioligandSmall moleculeVaccine
| Drug | Segment | Modality | Highest phase | Trials |
|---|---|---|---|---|
| Cyclophosphamide National Cancer Institute (NCI) | GD2 · Relapsed or refractory | Small molecule | Ph1/Ph2 | NCT04539366, NCT01953900, NCT07502287, NCT03721068 |
| Fludarabine Baylor College of Medicine | GD2 · Relapsed or refractory | Other or not recognised | Ph1/Ph2 | NCT01953900, NCT07502287, NCT03721068 |
| EB-DTNB-NK Beijing Biotech | GD2 · Relapsed or refractory | Other or not recognised | Ph1/Ph2 | NCT07502287 |
| GD2-CART01 Bambino Gesù Hospital and Research Institute | GD2 · Relapsed or refractory | Cell therapy | Ph1/Ph2 | NCT03373097 |
| i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells Baylor College of Medicine | GD2 · Relapsed or refractory | Cell therapy | Ph1 | NCT07211737, NCT07211737, NCT07211737 |
| Bevacizumab Universität Münster | GD2 · Relapsed or refractory | Antibody | Ph1 | NCT07897968 |
| C7R-GD2.CART cells Baylor College of Medicine | GD2 · Relapsed or refractory | Cell therapy | Ph1 | NCT03635632 |
| Chimeric Antigen Receptor (CAR) Therapy Infusion Universität Münster | GD2 · Relapsed or refractory | Other or not recognised | Ph1 | NCT07897968 |
| Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate Emory University | GD2 · Relapsed or refractory | Antibody | Ph1 | NCT05400603 |
| Fludarabine Phosphate National Cancer Institute (NCI) | GD2 · Relapsed or refractory | Other or not recognised | Ph1 | NCT04539366 |
| GD2 T cells Baylor College of Medicine | GD2 · Relapsed or refractory | Other or not recognised | Ph1 | NCT01953900 |
| GD2-CAR-expressing Autologous T-lymphocytes National Cancer Institute (NCI) | GD2 · Relapsed or refractory | Other or not recognised | Ph1 | NCT04539366 |
| iC9.GD2.CAR.IL-15 T-cells UNC Lineberger Comprehensive Cancer Center | GD2 · Relapsed or refractory | Other or not recognised | Ph1 | NCT03721068 |
| VZV vaccine Baylor College of Medicine | GD2 · Relapsed or refractory | Vaccine | Ph1 | NCT01953900 |
Assets over time
160 trials updated in the last 16 months. Each row is an asset; each dot is one of its trials at first posting, sized by phase. Orange is Phase 3.
| Asset | Lead sponsor | |
|---|---|---|
| Cyclophosphamide | National Cancer Institute (NCI) | |
| Busulfan | Children's Oncology Group | |
| Aldesleukin | National Cancer Institute (NCI) | |
| hu1418K322A + Temozolomide + Irinotecan | Renaissance Pharma Ltd. | |
| 18F-MFBG | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) | |
| 18F-DOPA | University of Alberta | |
| Dinutuximab beta, temozolomide, irinotecan, autologous NK cell | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | |
| Alectinib | Cancer Research UK | |
| Capmatinib | Cancer Research UK | |
| Dinutuximab | National Cancer Institute (NCI) | |
| Nivolumab | Instituto do Cancer do Estado de São Paulo | |
| Naxitamab | Shaare Zedek Medical Center | |
| Ensartinib | National Cancer Institute (NCI) | |
| Tipifarnib | National Cancer Institute (NCI) | |
| Palbociclib | Pfizer | |
| Eflornithine | Milton S. Hershey Medical Center | |
| Bevacizumab | University of Birmingham | |
| Filgrastim | New Approaches to Neuroblastoma Therapy Consortium | |
| Topotecan | Novartis Pharmaceuticals | |
| GM-CSF | Memorial Sloan Kettering Cancer Center | |
| Zanzalintinib | M.D. Anderson Cancer Center | |
| Apatinib, Irinotecan, Temozolomide | Sun Yat-sen University | |
| OPT-821 | Memorial Sloan Kettering Cancer Center | |
| 177Lu-DOTATATE | Jakob Stenman | |
| Enasidenib | National Cancer Institute (NCI) | |
| dasatinib | City of Hope Medical Center | |
| Zilovertamab vedotin | Merck Sharp & Dohme LLC | |
| Hu3F8 | Memorial Sloan Kettering Cancer Center | |
| GD2, PSMA and CD276 CAR-T cells | Shenzhen Geno-Immune Medical Institute | |
| Thiotepa | Masonic Cancer Center, University of Minnesota |
All trials
Site countries come from each record's listed locations. Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered.
| Trial | Phase | Sponsor | Status | Posted | Primary completion |
|---|---|---|---|---|---|
| SHINE · NCT07549321 A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients 7 countries, 40% of sites in the US Decision brief → | Ph2/Ph3 | Renaissance Pharma Ltd. | recruiting | 2026-04-24 | 2031-03 |
| NB-NK-2026 · NCT07375563 Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma Single-country: Russia (1 site) Decision brief → | Ph3 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | recruiting | 2026-01-29 | 2026-12-15 |
| DETERMINE · NCT06988475 DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations Single-country: United Kingdom (17 sites) Decision brief → | Ph2/Ph3 | Cancer Research UK | recruiting | 2025-05-23 | 2029-10 |
| NCT06172296 Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma 5 countries, 88% of sites in the US Decision brief → | Ph3 | National Cancer Institute (NCI) | recruiting | 2023-12-15 | 2029-12-31 |
| DETERMINE · NCT05770037 DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers Single-country: United Kingdom (27 sites) Decision brief → | Ph2/Ph3 | Cancer Research UK | recruiting | 2023-03-15 | 2029-10 |
| NCT04724369 Open-Label Study of 18F-mFBG for Imaging Neuroblastoma Single-country: United States (8 sites) Decision brief → | Ph3 | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) | completed | 2021-01-26 | 2026-07-30 |
| NCT04706910 18F-DOPA II - PET Imaging Optimization Single-country: Canada (1 site) Decision brief → | Ph3 | University of Alberta | recruiting | 2021-01-13 | 2027-12 |
| NCT03126916 Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) 3 countries, 93% of sites in the US Decision brief → | Ph3 | Children's Oncology Group | recruiting | 2017-04-25 | 2030-09-30 |
| NCT02176967 Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma 6 countries, 87% of sites in the US Decision brief → | Ph3 | Children's Oncology Group | active not recruiting | 2014-06-27 | 2026-09-30 |
| NCT01041638 Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma Single-country: United States (32 sites) Decision brief → | Ph3 | National Cancer Institute (NCI) | completed | 2010-01-01 | 2013-12-31 |
| NCT00026312 Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma 5 countries, 87% of sites in the US Decision brief → | Ph3 | National Cancer Institute (NCI) | completed | 2003-01-27 | 2012-01-12 |
| NCT07819838 Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations No sites listed Decision brief → | Ph1/Ph2 | Children's Oncology Group | not yet recruiting | 2026-09-15 | 2032-04-09 |
| NCT07635056 Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma Single-country: United States (1 site) Decision brief → | Ph2 | Children's Hospital Medical Center, Cincinnati | recruiting | 2026-06-09 | 2031-06 |
| NCT07537400 Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5 Single-country: Israel (1 site) Decision brief → | Ph2 | Shaare Zedek Medical Center | recruiting | 2026-04-17 | 2028-06 |
| NCT07527169 A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma Single-country: United States (1 site) Decision brief → | Ph2 | M.D. Anderson Cancer Center | recruiting | 2026-04-14 | 2028-07-01 |
| DUAL-NK-NB · NCT07502287 Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Beijing Biotech | recruiting | 2026-03-30 | 2027-03-14 |
| NCT07444918 Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors No sites listed Decision brief → | Ph2 | Tianjin Medical University Cancer Institute and Hospital | not yet recruiting | 2026-03-03 | 2027-12-01 |
| NCT07437963 Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse Single-country: United States (4 sites) Decision brief → | Ph1/Ph2 | National Cancer Institute (NCI) | recruiting | 2026-02-27 | 2029-09-30 |
| GLOW-FISH · NCT07399821 An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma Single-country: Netherlands (1 site) Decision brief → | Ph1/Ph2 | Princess Maxima Center for Pediatric Oncology | recruiting | 2026-02-10 | 2027-04-01 |
| BEACON2 · NCT07334301 A Multi-Arm, Platform Trial For Relapsed Neuroblastoma 5 countries, 0% of sites in the US Decision brief → | Ph1/Ph2 | University of Birmingham | recruiting | 2026-01-12 | 2030-12-31 |
| NCT07318831 Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children Single-country: China (1 site) Decision brief → | Ph2 | Tianjin Medical University Cancer Institute and Hospital | recruiting | 2026-01-06 | 2028-12-31 |
| NCT07261241 NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab Single-country: United States (13 sites) Decision brief → | Ph2 | New Approaches to Neuroblastoma Therapy Consortium | not yet recruiting | 2025-12-03 | 2030-12-31 |
| NEUROBLASTOTEP · NCT07111117 Comparison of 18F Labeled Analog of MIBG (18F-MFBG) PET/CT and 123I-MIBG SPECT in Pediatric Patients With Neuroblastoma. Single-country: France (3 sites) Decision brief → | Ph2 | Institut Curie | not yet recruiting | 2025-08-08 | 2028-09 |
| Orion · NCT07100704 Recurrent/Metastatic Olfactory Neuroblastoma: Evaluating the Efficacy and Safety of Nivolumab Single-country: Japan (2 sites) Decision brief → | Ph2 | National Cancer Center Hospital East | recruiting | 2025-08-03 | 2028-04-14 |
| NCT07085338 A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma Single-country: United States (5 sites) Decision brief → | Ph2 | St. Jude Children's Research Hospital | recruiting | 2025-07-25 | 2028-02-01 |
| NCT06858501 Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma No sites listed Decision brief → | Ph2 | Children's Oncology Group | withdrawn | 2025-03-05 | 2028-12-20 |
| RABBIT · NCT06814496 Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors Single-country: United States (3 sites) Decision brief → | Ph1/Ph2 | University of Arizona | recruiting | 2025-02-07 | 2030-05 |
| NCT06803875 Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma Single-country: United States (2 sites) Decision brief → | Ph1/Ph2 | Roberto Chiarle | recruiting | 2025-01-31 | 2027-12-31 |
| PEEL-224 · NCT06721689 PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors Single-country: United States (7 sites) Decision brief → | Ph1/Ph2 | Theodore Laetsch | recruiting | 2024-12-06 | 2030-04 |
| ANTARES · NCT06638931 Agnostic Therapy in Rare Solid Tumors Single-country: Brazil (5 sites) Decision brief → | Ph2 | Instituto do Cancer do Estado de São Paulo | active not recruiting | 2024-10-15 | 2027-07 |
| NCT06625190 Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | University of Florida | recruiting | 2024-10-03 | 2030-02 |
| LUPARPED · NCT06607692 Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). Single-country: Spain (1 site) Decision brief → | Ph1/Ph2 | Fundación de investigación HM | recruiting | 2024-09-23 | 2029-07 |
| NCT06541262 Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors 2 countries, 96% of sites in the US Decision brief → | Ph1/Ph2 | Milton S. Hershey Medical Center | recruiting | 2024-08-07 | 2030-11-01 |
| NCT06540963 Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma Single-country: United States (12 sites) Decision brief → | Ph2 | Giselle Sholler | recruiting | 2024-08-07 | 2030-12-01 |
| NCT06528496 N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma Single-country: United States (1 site) Decision brief → | Ph2 | Memorial Sloan Kettering Cancer Center | recruiting | 2024-07-30 | 2029-07-22 |
| NCT06465199 Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas Single-country: United States (14 sites) Decision brief → | Ph1/Ph2 | Milton S. Hershey Medical Center | recruiting | 2024-06-18 | 2033-05 |
| NCT06450041 NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial Single-country: United States (13 sites) Decision brief → | Ph2 | New Approaches to Neuroblastoma Therapy Consortium | recruiting | 2024-06-10 | 2028-12 |
| NCT06395103 Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) 23 countries, 24% of sites in the US Decision brief → | Ph1/Ph2 | Merck Sharp & Dohme LLC | recruiting | 2024-05-01 | 2029-03-31 |
| NCT06176989 Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors Single-country: United States (1 site) Decision brief → | Ph2 | National Cancer Institute (NCI) | recruiting | 2023-12-20 | 2027-12-31 |
| NCT06057948 A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma Single-country: United States (7 sites) Decision brief → | Ph2 | Memorial Sloan Kettering Cancer Center | recruiting | 2023-09-28 | 2027-03-21 |
| NCT05754684 Quadruple Immunotherapy for Neuroblastoma Single-country: Hong Kong (1 site) Decision brief → | Ph2 | Hong Kong Children's Hospital | recruiting | 2023-03-06 | 2025-12-31 |
| AMPLIFY-7P · NCT05726864 A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors Single-country: United States (28 sites) Decision brief → | Ph1/Ph2 | Elicio Therapeutics | active not recruiting | 2023-02-14 | 2026-04-20 |
| NCT05701306 APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors Single-country: China (3 sites) Decision brief → | Ph1/Ph2 | Ascentage Pharma Group Inc. | recruiting | 2023-01-27 | 2027-06-01 |
| NCT05642455 SPEARHEAD-3 Pediatric Study Single-country: United States (10 sites) Decision brief → | Ph1/Ph2 | USWM CT, LLC | recruiting | 2022-12-08 | 2026-10-01 |
| NCT05489887 Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma 4 countries, 81% of sites in the US Decision brief → | Ph2 | Giselle Sholler | recruiting | 2022-08-05 | 2029-09 |
| RAPID · NCT05421897 Rapid Administration Pilot for Infusing Dinutuximab Single-country: United States (7 sites) Decision brief → | Ph2 | Children's Hospital Los Angeles | active not recruiting | 2022-06-16 | 2028-11 |
| NCT05296564 Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers Single-country: Israel (1 site) Decision brief → | Ph1/Ph2 | Hadassah Medical Organization | recruiting | 2022-03-25 | 2027-12-30 |
| NCT05199584 A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations Single-country: United States (16 sites) Decision brief → | Ph2 | Endeavor Biomedicines, Inc. | completed | 2022-01-20 | 2024-02-20 |
| NCT05135975 A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors Single-country: United States (6 sites) Decision brief → | Ph2 | Nationwide Children's Hospital | recruiting | 2021-11-26 | 2026-07 |
| NCT05027386 Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study. Single-country: China (5 sites) Decision brief → | Ph1/Ph2 | Sun Yat-sen University | completed | 2021-08-30 | 2026-02-04 |
| NCT05012098 Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON). Single-country: United States (1 site) Decision brief → | Ph2 | National Cancer Institute (NCI) | completed | 2021-08-19 | 2024-07-09 |
| NCT04936529 A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma Single-country: United States (1 site) Decision brief → | Ph2 | Memorial Sloan Kettering Cancer Center | recruiting | 2021-06-23 | 2027-06-15 |
| LuDO-N · NCT04903899 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma 7 countries, 0% of sites in the US Decision brief → | Ph2 | Jakob Stenman | recruiting | 2021-05-27 | 2032-12-31 |
| NCT04901702 Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma 2 countries, 70% of sites in the US Decision brief → | Ph1/Ph2 | St. Jude Children's Research Hospital | recruiting | 2021-05-25 | 2026-12-31 |
| NCT04851119 Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Single-country: United States (21 sites) Decision brief → | Ph1/Ph2 | Children's Oncology Group | recruiting | 2021-04-20 | 2028-06-30 |
| NCT04637503 4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Shenzhen Geno-Immune Medical Institute | not yet recruiting | 2020-11-19 | 2029-12-31 |
| NCT04559217 68Ga-DOTATATE Neuroblastoma Imaging Pilot Single-country: Canada (3 sites) Decision brief → | Ph2 | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | recruiting | 2020-09-22 | 2027-12-15 |
| NCT04385277 Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL) 4 countries, 91% of sites in the US Decision brief → | Ph2 | Children's Oncology Group | active not recruiting | 2020-05-12 | 2023-06-30 |
| NCT04320888 Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial 3 countries, 99% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2020-03-25 | 2024-09-30 |
| NCT04301843 Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma 2 countries, 83% of sites in the US Decision brief → | Ph2 | Giselle Sholler | active not recruiting | 2020-03-10 | 2028-10-01 |
| NCT04284774 Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial 2 countries, 99% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2020-02-26 | 2024-03-31 |
| NCT04238819 A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma 8 countries, 48% of sites in the US Decision brief → | Ph1/Ph2 | Eli Lilly and Company | completed | 2020-01-23 | 2024-03-15 |
| STING · NCT04211675 NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Nationwide Children's Hospital | active not recruiting | 2019-12-26 | 2026-12 |
| NCT04195555 Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) 3 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2019-12-12 | 2025-03-31 |
| NCT04023331 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma Single-country: United States (8 sites) Decision brief → | Ph1/Ph2 | Clarity Pharmaceuticals Ltd | terminated | 2019-07-17 | 2025-01-24 |
| NCT03794349 Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma 5 countries, 86% of sites in the US Decision brief → | Ph2 | Children's Oncology Group | active not recruiting | 2019-01-07 | 2025-03-31 |
| NCT03786783 Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma 3 countries, 70% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | completed | 2018-12-26 | 2021-12-31 |
| NCT03709680 Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors 13 countries, 67% of sites in the US Decision brief → | Ph2 | Pfizer | completed | 2018-10-17 | 2024-08-26 |
| NCT03698994 Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) 2 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2018-10-09 | 2022-03-31 |
| NCT03526250 Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) 2 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | completed | 2018-05-16 | 2023-03-31 |
| NCT03373097 Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors Single-country: Italy (1 site) Decision brief → | Ph1/Ph2 | Bambino Gesù Hospital and Research Institute | active not recruiting | 2017-12-14 | 2026-12 |
| NCT03363373 Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow 9 countries, 10% of sites in the US Decision brief → | Ph2 | Y-mAbs Therapeutics | active not recruiting | 2017-12-06 | 2026-06-30 |
| NCT03213652 Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) 4 countries, 97% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2017-07-11 | 2025-09-30 |
| NCT03213704 Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) 2 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2017-07-11 | 2024-09-30 |
| NCT03213678 Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) 2 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | completed | 2017-07-11 | 2023-09-30 |
| NCT03213665 Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) 2 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | completed | 2017-07-11 | 2022-03-31 |
| NCT03210714 Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) 2 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2017-07-07 | 2023-09-30 |
| VERITAS · NCT03165292 Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction 5 countries, 0% of sites in the US Decision brief → | Ph2 | Gustave Roussy, Cancer Campus, Grand Paris | terminated | 2017-05-24 | 2023-08-28 |
| NCT03155620 Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) 4 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2017-05-16 | 2025-03-31 |
| NCT03033303 A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma Single-country: United States (1 site) Decision brief → | Ph2 | Memorial Sloan Kettering Cancer Center | completed | 2017-01-26 | 2025-09-29 |
| NMTT · NCT02679144 Neuroblastoma Maintenance Therapy Trial 2 countries, 87% of sites in the US Decision brief → | Ph2 | Giselle Sholler | active not recruiting | 2016-02-10 | 2028-02 |
| STARTRK-NG · NCT02650401 Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options 9 countries, 58% of sites in the US Decision brief → | Ph1/Ph2 | Hoffmann-La Roche | active not recruiting | 2016-01-08 | 2027-06-30 |
| NCT02605421 Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma Single-country: United States (1 site) Decision brief → | Ph2 | Masonic Cancer Center, University of Minnesota | recruiting | 2015-11-16 | 2027-10-01 |
| AflacST1502 · NCT02574728 Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors Single-country: United States (6 sites) Decision brief → | Ph2 | Emory University | active not recruiting | 2015-10-14 | 2026-06 |
| PEDS-PLAN · NCT02559778 Pediatric Precision Laboratory Advanced Neuroblastoma Therapy 2 countries, 86% of sites in the US Decision brief → | Ph2 | Giselle Sholler | recruiting | 2015-09-24 | 2030-09 |
| BEACON · NCT02308527 Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children 10 countries, 0% of sites in the US Decision brief → | Ph2 | University of Birmingham | completed | 2014-12-04 | 2021-08-01 |
| NCT01857934 Therapy for Children With Advanced Stage Neuroblastoma Single-country: United States (1 site) Decision brief → | Ph2 | St. Jude Children's Research Hospital | completed | 2013-05-20 | 2021-10-21 |
| NCT01804634 Reduced Intensity Haploidentical BMT for High Risk Solid Tumors Single-country: United States (3 sites) Decision brief → | Ph2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | recruiting | 2013-03-05 | 2027-01 |
| NCT01757626 Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Memorial Sloan Kettering Cancer Center | active not recruiting | 2012-12-31 | 2026-12 |
| ATOMIC · NCT01192555 Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Baylor College of Medicine | active not recruiting | 2010-09-01 | 2012-07 |
| TOTEM2 · NCT00918320 Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours Single-country: France (1 site) Decision brief → | Ph2 | Gustave Roussy, Cancer Campus, Grand Paris | completed | 2009-06-11 | 2013-10 |
| NCT00911560 Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Memorial Sloan Kettering Cancer Center | completed | 2009-06-02 | 2026-08-03 |
| NCT00840047 Methionine PET/CT Studies In Patients With Cancer Single-country: United States (1 site) Decision brief → | Ph2 | St. Jude Children's Research Hospital | active not recruiting | 2009-02-10 | 2027-07-27 |
| NCT00788125 Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | City of Hope Medical Center | terminated | 2008-11-10 | 2010-04-30 |
| NCT00407433 Clinical Studies of Gemcitabine-Oxaliplatin Single-country: France (1 site) Decision brief → | Ph2 | Gustave Roussy, Cancer Campus, Grand Paris | completed | 2006-12-05 | – |
| NCT00253435 N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma 2 countries, 93% of sites in the US Decision brief → | Ph2 | New Approaches to Neuroblastoma Therapy Consortium | completed | 2005-11-15 | 2012-12 |
| NCT00107289 Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma Single-country: United States (1 site) Decision brief → | Ph2 | Memorial Sloan Kettering Cancer Center | recruiting | 2005-04-06 | 2027-05 |
| GD2CART-BEV · NCT07897968 GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors Single-country: Germany (1 site) Decision brief → | Ph1 | Universität Münster | not yet recruiting | 2026-10-27 | 2031-09-30 |
| NCT07688252 Dinutuximab-beta and Chemotherapy in Newly Diagnosed High-Risk Neuroblastoma Single-country: Taiwan (2 sites) Decision brief → | Ph1 | Chang Gung Memorial Hospital | recruiting | 2026-07-07 | 2032-12-31 |
| MRG003 · NCT07584499 Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors Single-country: China (1 site) Decision brief → | Ph1 | Sun Yat-sen University | recruiting | 2026-05-13 | 2027-05-30 |
| ThINKK-01 · NCT07518654 Phase I Clinical Trial of ThINKK Adoptive Immunotherapy After Allogeneic Hematopoietic Transplantation in Children With Leukemia or Neuroblastoma Single-country: Canada (2 sites) Decision brief → | Ph1 | Michel Duval | not yet recruiting | 2026-04-08 | 2029-05-01 |
| NCT07358260 B7-H3.CD28Z.CART in Solid Tumors Single-country: United States (1 site) Decision brief → | Ph1 | Robbie Majzner | recruiting | 2026-01-22 | 2029-12-31 |
| NCT07211737 NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma Single-country: United States (1 site) Decision brief → | Ph1 | Baylor College of Medicine | recruiting | 2025-10-08 | 2029-04 |
| SABRE · NCT07172958 Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE) Single-country: United States (2 sites) Decision brief → | Ph1 | Children's National Research Institute | recruiting | 2025-09-15 | 2041-12 |
| NCT07087002 GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults Single-country: United States (1 site) Decision brief → | Ph1 | Stanford University | recruiting | 2025-07-25 | 2027-08 |
| NCT07027748 Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma Single-country: United States (2 sites) Decision brief → | Ph1 | Steven DuBois, MD | recruiting | 2025-06-18 | 2027-07-01 |
| PHOX2B · NCT07007117 PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma Single-country: United States (1 site) Decision brief → | Ph1 | Stephan Grupp MD PhD | active not recruiting | 2025-06-05 | 2032-06-30 |
| NCT06995872 Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma Single-country: United States (1 site) Decision brief → | Ph1 | National Cancer Institute (NCI) | recruiting | 2025-05-30 | 2028-06-01 |
| NCT06500819 Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors Single-country: United States (1 site) Decision brief → | Ph1 | Stanford University | recruiting | 2024-07-15 | 2029-07 |
| NCT06479811 [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers Single-country: United States (1 site) Decision brief → | Ph1 | National Cancer Institute (NCI) | recruiting | 2024-06-28 | 2029-01-01 |
| NCT06104488 A Study of Avutometinib for People With Solid Tumor Cancers Single-country: United States (2 sites) Decision brief → | Ph1 | Memorial Sloan Kettering Cancer Center | completed | 2023-10-27 | 2026-11-03 |
| NCT06041516 A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors Single-country: United States (1 site) Decision brief → | Ph1 | National Cancer Institute (NCI) | recruiting | 2023-09-18 | 2027-10-30 |
| MAGNETO · NCT05990751 Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma Single-country: United Kingdom (1 site) Decision brief → | Ph1 | University College, London | active not recruiting | 2023-08-14 | 2026-12 |
| GPC2 · NCT05650749 GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma Single-country: United States (1 site) Decision brief → | Ph1 | Stephan Grupp MD PhD | enrolling by invitation | 2022-12-14 | 2028-01-30 |
| NCT05608148 Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors Single-country: Japan (1 site) Decision brief → | Ph1 | Kyushu University | recruiting | 2022-11-08 | 2027-08-25 |
| NCT05429502 Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors 4 countries, 50% of sites in the US Decision brief → | Ph1 | Novartis Pharmaceuticals | terminated | 2022-06-23 | 2025-02-26 |
| Aflac-NBL-2002 · NCT05400603 Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma Single-country: United States (1 site) Decision brief → | Ph1 | Emory University | recruiting | 2022-06-01 | 2026-12 |
| NCT05130255 GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2 Single-country: United States (8 sites) Decision brief → | Ph1 | Y-mAbs Therapeutics | terminated | 2021-11-23 | 2026-03-11 |
| NCT04897321 B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) Single-country: United States (1 site) Decision brief → | Ph1 | St. Jude Children's Research Hospital | recruiting | 2021-05-21 | 2027-03-01 |
| AMPLIFY-201 · NCT04853017 A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors Single-country: United States (10 sites) Decision brief → | Ph1 | Elicio Therapeutics | completed | 2021-04-21 | 2023-01-26 |
| PEACH · NCT04837547 PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy Single-country: United States (3 sites) Decision brief → | Ph1 | University of Florida | recruiting | 2021-04-08 | 2027-09 |
| NCT04751383 Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma 2 countries, 82% of sites in the US Decision brief → | Ph1 | National Cancer Institute (NCI) | terminated | 2021-02-12 | 2024-09-30 |
| NCT04610736 TEMOkids Study : A Phase I Pediatric Study for KIMOZO, Oral Suspension of Temozolomide 5 countries, 0% of sites in the US Decision brief → | Ph1 | Orphelia Pharma | completed | 2020-10-30 | 2023-01-15 |
| NCT04544995 Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP) Single-country: United Kingdom (2 sites) Decision brief → | Ph1 | GlaxoSmithKline | terminated | 2020-09-10 | 2025-04-23 |
| NCT04539366 Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST Trial Single-country: United States (6 sites) Decision brief → | Ph1 | National Cancer Institute (NCI) | suspended | 2020-09-07 | 2040-12-31 |
| NCT04500548 Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study 2 countries, 78% of sites in the US Decision brief → | Ph1 | National Cancer Institute (NCI) | withdrawn | 2020-08-05 | 2022-06-21 |
| NCT04483778 B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults Single-country: United States (1 site) Decision brief → | Ph1 | Seattle Children's Hospital | active not recruiting | 2020-07-23 | 2040-12 |
| NCT04337177 Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors Single-country: United States (11 sites) Decision brief → | Ph1 | Valent Technologies, LLC | active not recruiting | 2020-04-07 | 2026-12 |
| NYMC195 · NCT04308330 Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies Single-country: United States (1 site) Decision brief → | Ph1 | New York Medical College | recruiting | 2020-03-16 | 2026-12-31 |
| NCT04239092 9-ING-41 in Pediatric Patients With Refractory Malignancies. Single-country: United States (9 sites) Decision brief → | Ph1 | Actuate Therapeutics Inc. | terminated | 2020-01-23 | 2025-07-07 |
| NCT04106219 A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma 9 countries, 41% of sites in the US Decision brief → | Ph1 | Eli Lilly and Company | active not recruiting | 2019-09-26 | 2022-04-13 |
| NCT04084067 Indocyanine Green (ICG) Guided Tumor Resection Single-country: United States (1 site) Decision brief → | Ph1 | St. Jude Children's Research Hospital | completed | 2019-09-10 | 2026-07-28 |
| NEUROBLU 02 · NCT03966651 A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors. Single-country: France (14 sites) Decision brief → | Ph1 | Institut Claudius Regaud | completed | 2019-05-29 | 2024-08-08 |
| NCT03721068 Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma Single-country: United States (2 sites) Decision brief → | Ph1 | UNC Lineberger Comprehensive Cancer Center | recruiting | 2018-10-26 | 2030-05-19 |
| NCT03635632 C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) Single-country: United States (2 sites) Decision brief → | Ph1 | Baylor College of Medicine | active not recruiting | 2018-08-17 | 2023-05-16 |
| NCT03618381 EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults Single-country: United States (1 site) Decision brief → | Ph1 | Seattle Children's Hospital | active not recruiting | 2018-08-07 | 2040-06 |
| CLOVER-2 · NCT03478462 Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas 3 countries, 75% of sites in the US Decision brief → | Ph1 | Cellectar Biosciences, Inc. | active not recruiting | 2018-03-27 | 2027-06-30 |
| GINAKIT2 · NCT03294954 GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma Single-country: United States (1 site) Decision brief → | Ph1 | Baylor College of Medicine | active not recruiting | 2017-09-27 | 2027-12 |
| NCT03107988 NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) 4 countries, 77% of sites in the US Decision brief → | Ph1 | New Approaches to Neuroblastoma Therapy Consortium | completed | 2017-04-11 | 2024-08-22 |
| MiniVan · NCT02914405 Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma 2 countries, 33% of sites in the US Decision brief → | Ph1 | University Hospital Southampton NHS Foundation Trust | active not recruiting | 2016-09-26 | 2025-06-30 |
| NCT02909777 Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma Single-country: United States (4 sites) Decision brief → | Ph1 | Dana-Farber Cancer Institute | completed | 2016-09-21 | 2025-12 |
| NEPENTHE · NCT02780128 Next Generation Personalized Neuroblastoma Therapy Single-country: United States (1 site) Decision brief → | Ph1 | Yael P Mosse | terminated | 2016-05-23 | 2022-08 |
| NCT02650648 Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma Single-country: United States (1 site) Decision brief → | Ph1 | Memorial Sloan Kettering Cancer Center | completed | 2016-01-08 | 2025-07-28 |
| NCT02573896 Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells Single-country: United States (11 sites) Decision brief → | Ph1 | New Approaches to Neuroblastoma Therapy Consortium | active not recruiting | 2015-10-12 | 2026-12 |
| NCT02508038 Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors Single-country: United States (1 site) Decision brief → | Ph1 | University of Wisconsin, Madison | recruiting | 2015-07-24 | 2026-12 |
| NCT02311621 Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01 Single-country: United States (1 site) Decision brief → | Ph1 | Seattle Children's Hospital | active not recruiting | 2014-12-08 | 2023-11 |
| N2013-02 · NCT02298348 Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma 2 countries, 92% of sites in the US Decision brief → | Ph1 | New Approaches to Neuroblastoma Therapy Consortium | active not recruiting | 2014-11-21 | 2026-12 |
| NCT02013336 Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors Single-country: United States (5 sites) Decision brief → | Ph1 | South Plains Oncology Consortium | recruiting | 2013-12-17 | 2026-12 |
| VEGAS · NCT01953900 iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma Single-country: United States (2 sites) Decision brief → | Ph1 | Baylor College of Medicine | active not recruiting | 2013-10-01 | 2019-10-31 |
| NCT01875601 NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors Single-country: United States (1 site) Decision brief → | Ph1 | National Cancer Institute (NCI) | completed | 2013-06-12 | 2015-09-08 |